Page last updated: 2024-11-05

tetramethylpyrazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tetramethylpyrazine (TMP) is a heterocyclic compound with the molecular formula C8H12N2. It is a white crystalline solid with a characteristic odor. TMP is a potent antioxidant and has been shown to possess a range of pharmacological properties, including anti-inflammatory, neuroprotective, and anti-cancer effects. TMP is naturally found in various foods, such as roasted coffee, roasted meat, and fermented soybean products. Its synthesis can be achieved through various methods, including the reaction of 2,3-dimethylpyrazine with methyl iodide. The biological activity of TMP has been extensively investigated, with studies focusing on its potential therapeutic applications in diseases such as Alzheimer's disease, Parkinson's disease, and diabetes. The unique structural features of TMP, including its electron-rich pyrazine ring and the presence of four methyl groups, contribute to its antioxidant and pharmacological activities. TMP is also a valuable research tool in the study of free radical scavenging and oxidative stress. Its importance in food chemistry lies in its contribution to the aroma and flavor of roasted foods. The compound is known to form volatile compounds during the Maillard reaction, a complex chemical process responsible for the browning of food during cooking. TMP has gained significant attention in research due to its wide range of biological effects, particularly its antioxidant properties, which make it a potential therapeutic agent for a variety of conditions. Furthermore, its abundance in various food sources and its role in the development of food flavor have contributed to its ongoing study.'

tetramethylpyrazine: found in Ligusticum chuanxiong [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tetramethylpyrazine : A member of the class of pyrazines that is pyrazine in which all four hydrogens have been replaced by methyl groups. An alkaloid extracted from Chuanxiong (Ligusticum wallichii). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
LigusticumgenusA plant genus of the family APIACEAE.[MeSH]ApiaceaeA large plant family in the order Apiales, also known as Umbelliferae. Most are aromatic herbs with alternate, feather-divided leaves that are sheathed at the base. The flowers often form a conspicuous flat-topped umbel. Each small individual flower is usually bisexual, with five sepals, five petals, and an enlarged disk at the base of the style. The fruits are ridged and are composed of two parts that split open at maturity.[MeSH]

Cross-References

ID SourceID
PubMed CID14296
CHEMBL ID303697
CHEBI ID133246
SCHEMBL ID77624
MeSH IDM0069117

Synonyms (80)

Synonym
AKOS003398567
MLS000069594 ,
smr000059042
nsc46451
nsc-46451
tetramethylpyrazine
tetramethylpyrazin
nsc-36080
2,5,6-tetramethylpyrazine
bs factor
1124-11-4
pyrazine, tetramethyl-
nsc36080
ligustizine
ligustrazine
chuanxiongzine
2,3,5,6-tetramethylpyrazine (natural)
fema no. 3237
nsc 36080
nsc 46451
2,3,5,6-tetramethyl pyrazine
tetrapyrazine
tmpz
einecs 214-391-2
AC-907/25014219
liqustrazine
2,3,5,6-tetramethylpyrazine
2,3,5,6-tetramethylpyrazine, natural, >=98%, fg
2,3,5,6-tetramethylpyrazine, >=98%, fg
2,3,5,6-tetramethylpyrazine, 98%
fema 3237
CHEBI:133246
2,3,5,6,-tetramethyl-1,4-pyrazine
AC-10515
inchi=1/c8h12n2/c1-5-6(2)10-8(4)7(3)9-5/h1-4h3
finhmkgkiniasc-uhfffaoysa-
2,3,5,6-tetramethyl-pyrazine
CHEMBL303697
T0972
A802574
NCGC00247063-01
v80f4ia5xg ,
unii-v80f4ia5xg
pyrazine, 2,3,5,6-tetramethyl-
cas-1124-11-4
tox21_302313
dtxsid6047070 ,
dtxcid4027070
NCGC00256097-01
BBL012277
STL163591
HMS2235K03
S3956
FT-0609443
AM20070299
chuanxingzine
chuanxiongqin
ligustrazine [who-dd]
2,3,5,6-tetramethylpyrazine [fcc]
ligustrazin
2,3,5,6-tetramethylpyrazine [fhfi]
HMS3371J08
CCG-207974
SCHEMBL77624
mfcd00006146
SY011353
Z1741976694
pyrazine, 2,3,5,6-tetramethyl
AC-34076
Q-100069
OPERA_ID_849
2,3,5,6-tetramethylpyrazine, analytical standard
2,3,5,6-tetramethylpyrazine, vetec(tm) reagent grade, 98%
tmp?
CS-W023183
HY-N0264
AS-13206
Q11319317
F11202
EN300-113945

Research Excerpts

Overview

Tetramethylpyrazine (TMP) is an amide alkaloid isolated from the traditional Chinese medicine Rhizoma Ligustici Chuanxiong, which has been widely used in the clinical treatment of ischemic cardiovascular disease. It is a flavoring additive that significantly contributes to the formation of flavor compounds in soybean-based fermented foods.

ExcerptReferenceRelevance
"Tetramethylpyrazine (TMP) is an amide alkaloid isolated from the traditional Chinese medicine Rhizoma Ligustici Chuanxiong, which has been widely used in the clinical treatment of ischemic cardiovascular disease."( Tetramethylpyrazine alleviates diabetes-induced high platelet response and endothelial adhesion via inhibiting NLRP3 inflammasome activation.
Chen, H; Chen, X; Fan, M; Sun, T; Sun, W; Tong, H; Wu, X; Yin, Z; Zhang, C; Zhang, H; Zheng, X; Zhu, Y, 2022
)
2.89
"Tetramethylpyrazine (TMP) is an alkaloid and one of the active components of CX."( Tetramethylpyrazine: A review on its mechanisms and functions.
Lin, J; Wang, Q; Xu, S; Yao, K; Zhou, S, 2022
)
2.89
"Tetramethylpyrazine (TTMP) is a flavoring additive that significantly contributes to the formation of flavor compounds in soybean-based fermented foods. "( rocF affects the production of tetramethylpyrazine in fermented soybeans with Bacillus subtilis BJ3-2.
Gong, X; Jin, J; Liu, Z; Tong, S; Wu, Y; Zhang, L; Zhong, J, 2022
)
2.45
"Tetramethylpyrazine (TMP) is a bioactive ingredient extracted from the plant Ligusticum wallichii, which has anti-diabetic and neuroprotective properties."( Tetramethylpyrazine ameliorates systemic streptozotocin-induced Alzheimer-like pathology.
Chen, H; Deng, C; Meng, S; Meng, Z, 2023
)
3.07
"Tetramethylpyrazine (TMP) is a kind of traditional Chinese medicine monomer with a good antioxidant and hepatoprotective function."( The Pathophysiological Changes and Clinical Effects of Tetramethylpyrazine in ICR Mice with Fluoride-Induced Hepatopathy.
Chang, LJ; Du, H; Fu, H; Li, H; Lin, J; Ni, X; Ou, Y; Shu, G; Xu, F; Zhang, S; Zhang, W; Zheng, Y, 2023
)
1.88
"Tetramethylpyrazine (TMP) is an important bioactive compound in vinegars, contributing to their health-enhancing attributes. "( Improved liquid-liquid extraction followed by HPLC-UV for accurate and eco-friendly determination of tetramethylpyrazine in vinegar products.
Cao, W; Wang, J; Yang, H, 2023
)
2.57
"Tetramethylpyrazine (TMP) is a compound purified from herb. "( Effect of tetramethylpyrazine (TMP) on Ca
Chou, CT; Fang, YC; Hsu, SS; Jan, CR; Kuo, CC; Liang, WZ; Wang, JL, 2017
)
2.3
"Tetramethylpyrazine (TMP) is a biologically active ingredient, which is isolated from a popularChinese medicinal plant. "( Tetramethylpyrazine inhibited hypoxia-induced expression of calcium-sensing receptors in pulmonary artery smooth muscle cells in chickens.
Abbas, RZ; Adnan, M; Ali, MM; Chang, Z; Duan, Z; Guo, R; Liu, Z; Mehmood, K; Qasim, MU; Shaheen, S; Tian, Y; Yang, MK; Yuan, F; Zhang, H,
)
3.02
"Tetramethylpyrazine (TMP) is a natural compound with neuroprotective effects but with unknown mechanisms on its antidepressant-like effect."( Tetramethylpyrazine ameliorates depression by inhibiting TLR4-NLRP3 inflammasome signal pathway in mice.
Dang, H; Fu, S; Hao, C; Jiang, S; Wang, J, 2019
)
2.68
"Tetramethylpyrazine (TMP) is a traditional Chinese medicine with anti-inflammation and immunomodulatory effects. "( Tetramethylpyrazine relieves LPS-induced pancreatic β-cell Min6 injury via regulation of miR-101/MKP-1.
Cao, D; Chen, D; Sui, P, 2019
)
3.4
"Tetramethylpyrazine (TMP) is a biologically active alkaloid isolated from Ligusticum wallichii."( Intravenous administration of tetramethylpyrazine reduces intestinal ischemia-reperfusion injury in rats.
Gál, P; Guzy, J; Pekárová, T; Tomečková, V; Tóth, Š; Varga, J; Veselá, J, 2013
)
1.4
"Tetramethylpyrazine (TMP) is an effective component of the traditional Chinese medicine Chuanxiong, which has been reported to have beneficial effects in various types of cancer. "( Tetramethylpyrazine inhibits osteosarcoma cell proliferation via downregulation of NF-κB in vitro and in vivo.
Fu, Q; Wang, Y; Zhao, W, 2013
)
3.28
"Tetramethylpyrazine (TMP) is an effective Chinese plant-derived medicine for colitis in the clinic, but the underlying molecular mechanisms of its use remain poorly understood. "( Tetramethylpyrazine improves oxazolone-induced colitis by inhibiting the NF-κB pathway.
Chen, N; Chen, W; Lu, Y; Yin, L; Zhu, J; Zhu, M, 2014
)
3.29
"Tetramethylpyrazine (TMP) is an active compound isolated from a Chinese herbal prescription that is widely used in traditional Chinese medicine for the treatment of inflammatory and cardiovascular diseases. "( Tetramethylpyrazine ameliorates high glucose-induced endothelial dysfunction by increasing mitochondrial biogenesis.
Gao, X; Li, X; Liu, Z; Wang, W; Xia, P; Xu, Q, 2014
)
3.29
"Tetramethylpyrazine (TMP) is a biological component that has been extracted from Ligusticum wallichii Franchat (ChuanXiong), which exhibits anti-apoptotic and antioxidant roles."( Neuroprotective effects of tetramethylpyrazine against dopaminergic neuron injury in a rat model of Parkinson's disease induced by MPTP.
Bi, L; Lu, C; Miao, Q; Miao, S; Shi, X; Wang, S; Xie, Y; Yang, Q; Zhang, J; Zhang, M; Zhang, S; Zhou, X, 2014
)
1.42
"Tetramethylpyrazine (TMP) is an active compound extracted from the traditional Chinese medicinal herb Chuanxiong. "( Tetramethylpyrazine promotes SH-SY5Y cell differentiation into neurons through epigenetic regulation of Topoisomerase IIβ.
Cao, C; Cui, H; Han, S; Jia, Z; Wang, Y; Xu, Y; Yan, Y; Zhao, J; Zhou, N, 2014
)
3.29
"Tetramethylpyrazine (TMP) is an identified component of Ligusticum wallichii with neuroprotective effects."( Tetramethylpyrazine Produces Antidepressant-Like Effects in Mice Through Promotion of BDNF Signaling Pathway.
Chen, XF; Huang, C; Jiang, B; Tong, LJ; Zhang, W, 2015
)
2.58
"Tetramethylpyrazine (TMP) is a major biologically active ingredient purified from the rhizome of Ligusticum wallichii (called Chuang Xiong in Chinese)."( Tetramethylpyrazine Ameliorated Hypoxia-Induced Myocardial Cell Apoptosis via HIF-1α/JNK/p38 and IGFBP3/BNIP3 Inhibition to Upregulate PI3K/Akt Survival Signaling.
Chen, WK; Day, CH; Huang, CY; Jiang, AZ; Kuo, WW; Lin, JY; Lin, KH; Padma, VV; Pai, P; Shen, CY, 2015
)
2.58
"Tetramethylpyrazine (TMP) is an active compound extracted from the traditional Chinese medicinal herb Chuanxiong. "( Tetramethylpyrazine induces SH-SY5Y cell differentiation toward the neuronal phenotype through activation of the PI3K/Akt/Sp1/TopoIIβ pathway.
Cao, CL; Cui, HX; Han, S; Jia, ZQ; Wang, YL; Xu, YN; Yan, YL; Yan, YX; Yao, SJ; Zhao, J; Zhao, JX; Zhou, NJ, 2015
)
3.3
"Tetramethylpyrazine (TMP) is a natural product extracted from Rhizoma Chuanxiong. "( Investigating the passage of tetramethylpyrazine-loaded liposomes across blood-brain barrier models in vitro and ex vivo.
Cheng, Y; Cheng, Z; Xia, H; Xu, Y, 2016
)
2.17
"Tetramethylpyrazine is a bioactive compound found in Chinese black vinegar. "( Effects of tetramethylpyrazine from Chinese black vinegar on antioxidant and hypolipidemia activities in HepG2 cells.
Chen, J; Ge, H; Liu, R; Tian, J; Xiao, J, 2017
)
2.29
"Tetramethylpyrazine (TMP) is a compound purified from the rhizome of Ligusticum wallichi (called chuanxiong in Chinese)."( Antioxidation and anti-inflammation by haem oxygenase-1 contribute to protection by tetramethylpyrazine against gentamicin-induced apoptosis in murine renal tubular cells.
Chang, CC; Chen, CH; Cheng, CF; Chou, Y; Juan, SH; Sue, YM, 2009
)
1.3
"Tetramethylpyrazine is a bioactive constituent isolated from the root of Ligusticum chuanxiong Hort, a Chinese herb."( Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells.
Guo, LY; Li, HL; Liu, M; Liu, Y; Wang, JN; Wang, SS; Wang, XB; Xiang, JZ; Zhang, QF; Zheng, F, 2010
)
1.44
"Tetramethylpyrazine (TMP) is a principal ingredient of Ligusticum wallichi Franchat (a Chinese herb), used for treatment of cardiovascular and cerebrovascular ischemic diseases."( Stabilization of mitochondrial function by tetramethylpyrazine protects against kainate-induced oxidative lesions in the rat hippocampus.
An, GS; Jia, HT; Jia, YH; Li, SY; Ni, JH; Sun, WG; Tang, Y, 2010
)
1.34
"Tetramethylpyrazine (TMP) is a major active ingredient extracted from Ligusticum wallichi Franchat."( The protective effect of tetramethylpyrazine on cartilage explants and chondrocytes.
Ao, YF; Cui, GQ; Deng, M; Hu, YL; Ju, XD; Wang, JQ; Yu, CL; Yu, JK, 2010
)
1.39
"Tetramethylpyrazine (TMP) is a reactive oxygen species (ROS) antagonist that has potent properties for the treatment of a variety of vascular diseases, such as ischemic stroke and pulmonary hypertension secondary to chronic obstructive pulmonary diseases. "( Tetramethylpyrazine inhibits hypoxia-induced pulmonary vascular leakage in rats via the ROS-HIF-VEGF pathway.
Deng, M; Zhang, L; Zhou, S, 2011
)
3.25
"Tetramethylpyrazine (TTMP) is a widely used flavoring additive with a nutty and roasted taste. "( Precursor supply strategy for tetramethylpyrazine production by bacillus subtilis on solid-state fermentation of wheat bran.
Hao, F; Wu, Q; Xu, Y, 2013
)
2.12
"Tetramethylpyrazine (TMPZ) is an active ingredient isolated from a commonly used Chinese herb, Ligusticum wallichii Franchat, which has long been used in China for the treatment of vascular diseases. "( Inhibitory mechanisms of tetramethylpyrazine in middle cerebral artery occlusion (MCAO)-induced focal cerebral ischemia in rats.
Chen, YC; Chou, DS; Hsiao, G; Lin, CH; Lin, JH; Lin, KH; Sheu, JR, 2006
)
2.08
"Tetramethylpyrazine (TMP) is a compound purified from the rhizome of Ligusticum wallichi (Chuanxiong) and has been found to protect against ischaemia-reperfusion injury, nephritis and alcohol-induced toxicity in rat kidneys."( Tetramethylpyrazine protects rat renal tubular cell apoptosis induced by gentamicin.
Chen, CH; Chen, TH; Chu, YL; Hou, CC; Hsu, YH; Juan, SH; Lin, H; Sue, YM, 2007
)
2.5
"Tetramethylpyrazine (TMPZ) is an active component of certain plants previously found to have inhibitory effects on platelet function using both in vivo and in vitro assays(1). "( Antiplatelet structure-activity relationship of tetramethylpyrazine.
Liu, SY; Sylvester, DM, 1994
)
1.99
"Tetramethylpyrazine (TMPZ) is an active ingredient of a Chinese herbal medicine. "( Antiplatelet activity of tetramethylpyrazine.
Liu, SY; Sylvester, DM, 1994
)
2.03
"Tetramethylpyrazine (TMP) is a compound purified from a medicinal plant Ligusticum wallichii Franch. "( Tetramethylpyrazine, a calcium antagonist.
Chiu, KW; Pang, PK; Shan, JJ, 1996
)
3.18
"Tetramethylpyrazine (TMPZ) is an active ingredient of a Chinese herbal medicine (Ligusticum wallichii Franchat). "( The antiplatelet activity of tetramethylpyrazine is mediated through activation of NO synthase.
Hung, WC; Kan, YC; Lin, CH; Sheu, JR; Yen, MH, 2000
)
2.04
"Tetramethylpyrazine (TMPZ) is an active component that can be extracted from certain plants. "( Antithrombotic/antiplatelet activity of tetramethylpyrazine.
Liu, SY; Sylvester, DM, 1990
)
1.99

Effects

Tetramethylpyrazine also has a certain inhibitory effect on thrombosis. It can reduce inflammation through the up-regulation of IL-10.

Tetramethylpyrazine (TMP) has been proven to be an anticancer agent in many studies. It has been used in traditional Chinese medicine to treat cardiovascular diseases such as atherosclerosis and hypertension. Tetramethyl pyrazine has been suggested to have neuroprotective effects against spinal cord injury (SCI)

ExcerptReferenceRelevance
"Tetramethylpyrazine also has a certain inhibitory effect on thrombosis."( [Protective mechanism of tetramethylpyrazine on cardiovascular system].
Ji, K; Li, J; Luo, CC; Pan, QQ; Tian, Z; Yang, CK; Zhou, HY, 2023
)
1.93
"Tetramethylpyrazine has an acceptable influence in reducing inflammation through the up-regulation of IL-10."( Efficacy of some non-conventional herbal medications (sulforaphane, tanshinone IIA, and tetramethylpyrazine) in inducing neuroprotection in comparison with interleukin-10 after spinal cord injury: A meta-analysis.
Koushki, D; Latifi, S; Matin, M; Norouzi Javidan, A, 2015
)
1.36
"Tetramethylpyrazine also has a certain inhibitory effect on thrombosis."( [Protective mechanism of tetramethylpyrazine on cardiovascular system].
Ji, K; Li, J; Luo, CC; Pan, QQ; Tian, Z; Yang, CK; Zhou, HY, 2023
)
1.93
"Tetramethylpyrazine has been reported to inhibit endoplasmic reticulum (ER) stress and high glucose-induced inflammation, which are closely associated with GDM."( Tetramethylpyrazine attenuates placental oxidative stress, inflammatory responses and endoplasmic reticulum stress in a mouse model of gestational diabetes mellitus.
Du, J; Jiao, Y; Zhang, J; Zhang, S, 2019
)
2.68
"Tetramethylpyrazine (TMP) has been effectively used for treating spinal cord injury (SCI) due to its anti-inflammatory, antioxidant, and neuroprotective activity. "( TAT-modified tetramethylpyrazine-loaded nanoparticles for targeted treatment of spinal cord injury.
Bai, X; Du, X; Li, C; Li, J; Lin, Y; Liu, Z; Wan, Y; Wei, J; Zhong, Z; Zhou, M, 2021
)
2.43
"Tetramethylpyrazine (TMP) has exhibited various anticancer effects. "( Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1.
Ji, Z; Li, H; Xiao, Y; Yan, W; Zhou, Y; Zhou, Z, 2017
)
3.34
"Tetramethylpyrazine (TMP) has anti-inflammatory effects and is used to treat cerebral ischemic injury, but the mechanism of TMP on neural protection is not clear. "( Inhibitory effects of tetramethylpyrazine on pain transmission of trigeminal neuralgia in CCI-ION rats.
Gao, Y; Guan, S; He, L; Huang, L; Jin, Y; Li, G; Liang, S; Liu, S; Ou, X; Shen, Y; Tan, M; Xiong, W; Xu, C; Xu, H; Yang, G, 2017
)
2.21
"Tetramethylpyrazine (TMP) has been used in the clinical treatment of vascular diseases."( Tetramethylpyrazine Showed Therapeutic Effects on Sepsis-Induced Acute Lung Injury in Rats by Inhibiting Endoplasmic Reticulum Stress Protein Kinase RNA-Like Endoplasmic Reticulum Kinase (PERK) Signaling-Induced Apoptosis of Pulmonary Microvascular Endoth
Liu, K; Liu, W; Shan, L; Tang, J; Zhang, S, 2018
)
2.64
"TMP (Tetramethylpyrazine) has been reported to have therapeutical effect on AS."( The Influence of Hyperlipidemia on Endothelial Function of FPN1 Tek-Cre Mice and the Intervention Effect of Tetramethylpyrazine.
Chen, SL; Guo, CY; Liu, X; Miao, Y; Sun, MY; Wang, JS; Yin, HJ; Zhang, M; Zhang, SP, 2018
)
1.15
"Tetramethylpyrazine (TMP) has been demonstrated to ameliorate cerebral ischemic injury and spinal cord injury by inhibiting inflammatory cell activation and pro-inflammatory cytokine production."( Tetramethylpyrazine ameliorates experimental autoimmune encephalomyelitis by modulating the inflammatory response.
Bai, XY; Cao, Z; Du, PC; Hou, Y; Wang, XF; Zhang, LS, 2018
)
2.64
"Tetramethylpyrazine (TMP) has been studied in depth and is widely used in the treatment of many kinds of diseases in China. "( Tetramethylpyrazine attenuates blood-brain barrier disruption in ischemia/reperfusion injury through the JAK/STAT signaling pathway.
Chen, Q; Gao, L; Gong, P; Han, S; Li, M; Liao, J; Tian, Q; Xu, Z; Zhang, Z; Zou, Y, 2019
)
3.4
"Tetramethylpyrazine (TMP) has been effectively used to ameliorate the damage on intestinal mucosa injury in rats with acute necrotizing pancreatitis (ANP)."( Tetramethylpyrazine (TMP) protects rats against acute pancreatitis through NF-κB pathway.
Chen, L; Chen, Y; Jianli, Z; Yun, H, 2019
)
2.68
"Tetramethylpyrazine (TMP) has been reported to attenuate harmful changes in ALI rats."( Tetramethylpyrazine alleviates LPS-induced inflammatory injury in HUVECs by inhibiting Rho/ROCK pathway.
Chen, J; Chen, Y; Fan, Y; Gao, C; Li, W; Liu, D; Pan, S; Wang, H, 2019
)
2.68
"As tetramethylpyrazine (TMP) has been recently found to be renoprotective and anti-apoptotic in multiple kidney injuries, we hypothesized that TMP would prevent CIN."( Tetramethylpyrazine prevents contrast-induced nephropathy by inhibiting p38 MAPK and FoxO1 signaling pathways.
Fu, D; Gong, X; Lu, H; Norgren, S; Tang, X; Wang, G; Wang, Q; Wang, Y, 2013
)
2.35
"Tetramethylpyrazine (TMP) has been used to treat ischemic stroke. "( Tetramethylpyrazine reduces cellular inflammatory response following permanent focal cerebral ischemia in rats.
Chang, CY; Chen, CJ; Chen, WY; Kao, TK; Kuan, YH; Li, GZ; Liao, SL; Ou, YC; Pan, HC, 2013
)
3.28
"As tetramethylpyrazine (TMP) has recently been found to be a renal protectant in multiple kidney injuries, we hypothesize that TMP could suppress arsenic nephrotoxicity."( Tetramethylpyrazine (TMP) protects against sodium arsenite-induced nephrotoxicity by suppressing ROS production, mitochondrial dysfunction, pro-inflammatory signaling pathways and programed cell death.
Davidson, MM; Gong, X; Hei, TK; Ivanov, VN, 2015
)
2.37
"Tetramethylpyrazine has an acceptable influence in reducing inflammation through the up-regulation of IL-10."( Efficacy of some non-conventional herbal medications (sulforaphane, tanshinone IIA, and tetramethylpyrazine) in inducing neuroprotection in comparison with interleukin-10 after spinal cord injury: A meta-analysis.
Koushki, D; Latifi, S; Matin, M; Norouzi Javidan, A, 2015
)
1.36
"Tetramethylpyrazine (TMP) has been widely used in China as a drug for the treatment of various diseases. "( Tetramethylpyrazine suppresses transient oxygen-glucose deprivation-induced connexin32 expression and cell apoptosis via the ERK1/2 and p38 MAPK pathway in cultured hippocampal neurons.
Cai, L; Dai, X; Dong, H; Gong, G; Gong, H; Ran, M; Wu, W; Yuan, L; Zhang, Y, 2014
)
3.29
"Tetramethylpyrazine has been suggested to have a therapeutic effect on impaired hearing that is induced by aminoglycoside antibiotics. "( Attenuation of streptomycin ototoxicity by tetramethylpyrazine in guinea pig cochlea.
Cui, C; Liu, D; Qin, X, 2015
)
2.12
"Tetramethylpyrazine (TMP) has been proven to be an anticancer agent in many studies. "( Tetramethylpyrazine inhibits the proliferation of acute lymphocytic leukemia cell lines via decrease in GSK-3β.
Chen, HX; Wang, XJ; Xu, YH; Yang, GC; Zhang, P, 2015
)
3.3
"Tetramethylpyrazine (TMP) has been suggested to have neuroprotective effects against spinal cord injury (SCI); however, few studies have examined these effects and the corresponding mechanism. "( The Neuroprotective Effect of Tetramethylpyrazine Against Contusive Spinal Cord Injury by Activating PGC-1α in Rats.
Cao, Y; Hu, J; Lang, Y; Lu, H; Zhang, T, 2015
)
2.15
"Tetramethylpyrazine (TMP) has curative effects on various diseases."( Tetramethylpyrazine prevents ethanol-induced hepatocyte injury via activation of nuclear factor erythroid 2-related factor 2.
Chen, L; Chen, Q; Jiang, Y; Jin, H; Lian, N; Lu, C; Lu, Y; Shao, J; Wu, L; Wu, X; Zhang, F; Zheng, S, 2015
)
2.58
"Tetramethylpyrazine has been widely used in traditional Chinese medicine to treat cardiovascular diseases such as atherosclerosis and hypertension. "( The effect of tetramethylpyrazine on hydrogen peroxide-induced oxidative damage in human umbilical vein endothelial cells.
Ding, ST; Li, WM; Li, XY; Liu, HT; Teng, YZ; Wu, JY; Xu, G; Yu, C, 2010
)
2.16
"Tetramethylpyrazine (TMP) has been used in traditional Chinese medicine as an analgesic for dysmenorrhea. "( Effect of tetramethylpyrazine on acute nociception mediated by signaling of P2X receptor activation in rat.
Gao, Y; Liang, SD; Mu, SN; Xu, BH; Xu, CS, 2004
)
2.17
"Tetramethylpyrazine has the effect of reducing the fibrosis degree of atrial tissue in dogs with CHF, and this efficacy may be related to the mechanism of decreasing the frequency of AF and shortening the AF duration."( [Effects of tetramethylpyrazine on fibrosis of atrial tissue and atrial fibrillation in a canine model of congestive heart failure induced by ventricular tachypacing].
Chen, L; Deng, YL; Du, J; Huang, H; Lin, YZ; Xu, CX, 2006
)
2.16
"Tetramethylpyrazine has been suggested to be neuroprotective for central neurons by acting as an antioxidant and a calcium antagonist."( Protective effects of tetramethylpyrazine on rat retinal cell cultures.
Ge, J; Tan, Z; Yang, Z; Zhang, Q, 2008
)
1.38

Actions

Tetramethylpyrazine could inhibit the secretion of VEGF by LPS-induced macrophages. The mechanism must be associated with inhibiting the expression of HIF-1alpha. Tetramethyl pyrazine promotes bone marrow repair by regulating Fas cell apoptosis signals.

ExcerptReferenceRelevance
"Tetramethylpyrazine promotes bone marrow repair by regulating Fas cell apoptosis signals, which further expands the traditional Chinese medicine theory of "removing blood stasis to create new.""( [Tetramethylpyrazine promotes bone marrow repair in a C57 mouse model of X-rayinduced immune-mediated bone marrow failure].
Chen, S; Gao, L; Hu, X; Nie, L; Zhang, X; Zhu, L, 2019
)
2.15
"Tetramethylpyrazine (TMP) plays a neuroprotective role in SCI; however, the underlying mechanism has not been fully elucidated."( Tetramethylpyrazine Facilitates Functional Recovery after Spinal Cord Injury by Inhibiting MMP2, MMP9, and Vascular Endothelial Cell Apoptosis.
Cao, Y; Hu, JZ; Li, DZ; Lu, HB; Wang, XK; Wu, TD; Xu, DQ; Zhang, T, 2017
)
2.62
"And tetramethylpyrazine may suppress the calcium ion overloading but not the activity of NOS associated with disuse muscular atrophy."( [Effects of tetramethylpyrazine on nitric oxide synthase activity and calcium ion concentration of skeletal muscle in hindlimb unloading rats].
Cui, JH; Gao, YF; Wu, X; Zhao, XH, 2012
)
1.24
"Tetramethylpyrazine could inhibit the secretion of VEGF by LPS-induced macrophages, and the mechanism must be associated with inhibiting the expression of HIF-1alpha. "( [Effects of tetramethylpyrazine on expression of vascular endothelial growth factor and hypoxia-induced factor-1alpha by rat peritoneal macrophages].
Chen, G; Chen, WH; Feng, JD; Hu, YY; Xu, XY; Ye, L, 2006
)
2.16

Treatment

Pretreatment with tetramethylpyrazine (TMP, 12 mg/kg/day) significantly reduced the incidence of ischemia-induced ventricular tachycardia (VT) and fibrillation (VF) from 100% and 50% of control hearts to 41% and 0% in the ischemic rat heart.

ExcerptReferenceRelevance
"Tetramethylpyrazine-pretreated rats showed higher values of FA, MD, Da, MK, and Ka in the cortex, lower MK, Ka, Kr, and FA values and higher MD,Da values in the hippocampus than the lipopolysaccharide group."( Diffusion kurtosis imaging to evaluate the effect and mechanism of tetramethylpyrazine on cognitive impairment induced by lipopolysaccharide in rats.
Dong, J; Guan, X; Li, G; Liang, M; Liu, S; Zhou, Q, 2021
)
1.58
"Pretreatment with tetramethylpyrazine increased the 6-Keto-PGF1a concentration to 266 +/- 51 pg/ml (143% of control heart), 471 +/- 89 pg/ml (150% of control heart) and 332 +/- 47 pg/ml (195% of control heart) at 15 min of normoxia, 2 min of hypoxia and 5 min of reoxygenation, respectively (p < 0.05 vs control)."( Effects of tetramethylpyrazine on the release of PGI2 and TXA2 in the hypoxic isolated rat heart.
Feng, J; Liu, R; Tang, S; Wu, G, 1997
)
1.01
"Pretreatment with tetramethylpyrazine (TMP, 12 mg/kg/day), a drug originally derived from the rhizomes of Ligusticum wallichii, significantly reduced the incidence of ischemia-induced ventricular tachycardia (VT) and fibrillation (VF) from 100% and 50% of control hearts to 41% (p < 0.05) and 0% (p < 0.05), respectively, in the ischemic rat heart. "( The effects of tetramethylpyrazine on the incidence of arrhythmias and the release of PGI2 and TXA2 in the ischemic rat heart.
Feng, J; Tang, S; Wu, G, 1999
)
0.99

Toxicity

ExcerptReferenceRelevance
"The toxic effect of cyclosporine A (CsA) on pancreatic islet beta-cells and the preventive effect of ligustrazine (LIG) on CsA-associated beta-cell toxicity in SD rats were investigated."( [Prevention of toxicity of cyclosporine A on rat pancreatic islet beta-cells by Ligustrazine].
Gu, MJ; Liu, ZM, 1993
)
0.29
" The vibrating solid micro-needle was effective and safe for the transdermal administration of hydrophilic drugs."( Skin drug permeability and safety through a vibrating solid micro-needle system.
Chen, K; Liu, TT; Wang, Q, 2018
)
0.48
" The current work shows that antioxidant additives can reduce the toxic effect of CPAs on porcine chondrocytes."( Evaluation of five additives to mitigate toxicity of cryoprotective agents on porcine chondrocytes.
Dong, R; Elliott, JAW; Jomha, NM; Laouar, L; Wu, K, 2019
)
0.51
"This meta-analysis demonstrated that SMLHI may be more effective and safe for the treatment of perioperative period of fracture."( Efficacy and safety of the injection of the traditional Chinese medicine salviae miltiorrhizae and ligustrazine hydrochloride for the treatment of perioperative period of fracture: A meta-analysis of randomized controlled trials.
Chen, S; Ding, S; Xie, J, 2020
)
0.56
"Based on the existing evidence, that Salvia miltiorrhiza and ligustrazine injection in the adjuvant treatment of early-stage diabetic kidney disease is safe and effective."( Efficacy and safety of Salvia miltiorrhiza (Salvia miltiorrhiza Bunge) and ligustrazine injection in the adjuvant treatment of early-stage diabetic kidney disease: A systematic review and meta-analysis.
Dai, S; Dong, F; Jin, B; Xie, F; Zhang, B; Zhang, T, 2021
)
0.62

Pharmacokinetics

The elimination half-life of tetramethylpyrazine (TMP) in rat blood and brain was 82. The present method has been successfully used to provide pharmacokinetic data after oral administration of TMPZ and TMPP tablets to dogs.

ExcerptReferenceRelevance
" The pharmacokinetic properties were investigated in the remaining control group and test group."( [Pharmacokinetic characteristics of tetramethylpyrazine and study on hemorheology in rat model of spleen deficiency syndrome].
Huang, X; Ren, P; Wen, AD, 1994
)
0.56
" It might be one of the pharmacokinetic mechanisms of TMP in the SDS model of rats."( [Pharmacokinetic characteristics of tetramethylpyrazine and study on hemorheology in rat model of spleen deficiency syndrome].
Huang, X; Ren, P; Wen, AD, 1994
)
0.56
""Blood stasis syndrome pharmacokinetics" means the pathophysiological state of blood stasis syndrome affectes significantly the pharmacokinetic parameters."( [Study on pharmacokinetic characteristics of tetramethylpyrazine and hemodynamics of heart blood stasis in dogs].
Huang, X; Jiang, YP; Zang, YM, 1996
)
0.55
"To explore relationship between the essence of Spleen Deficiency Syndrome (SDS) and pharmacokinetic characteristics (PK)."( [Effect of sijunzi decoction on motilin and pharmacokinetic characteristics of tetramethylpyrazine in rat model of spleen deficiency syndrome].
Huang, X; Jiang, YP; Ren, P, 1997
)
0.52
" The elimination half-life of tetramethylpyrazine in rat blood and brain were 82."( Pharmacokinetics of tetramethylpyrazine in rat blood and brain using microdialysis.
Liang, C; Tsai, TH, 2001
)
0.92
" The present method has been successfully used to provide pharmacokinetic data after oral administration of tetramethylpyrazine phosphate pulsincap capsules and immediate-release tablets to dogs."( Simple high-performance liquid chromatographic method for the determination of tetramethylpyrazine phosphate in very small volumes of dog plasma: application to a pharmacokinetic study.
Ding, H; Wu, F; Zhang, Z, 2006
)
0.77
" Main pharmacokinetic parameters were calculated and compared by statistic analysis."( [The effect of tetramethylpyrazine on the pharmacokinetics of intragastrically administered cyclosporine A in rats].
He, J; Liu, XL; Peng, WX; Song, J; Tang, J; Xu, P, 2006
)
0.69
"In the group of water pretreated and co-administrated with CsA, no significantly different pharmacokinetic parameters of CsA were found."( [The effect of tetramethylpyrazine on the pharmacokinetics of intragastrically administered cyclosporine A in rats].
He, J; Liu, XL; Peng, WX; Song, J; Tang, J; Xu, P, 2006
)
0.69
" The method described is successfully applied to the pharmacokinetic study of mouse plasma and brain tissue after oral administration of the Fufang TMPP and TMPP tablets to mice."( A simple gas chromatographic method for the simultaneous determination and pharmacokinetic study of tetramethylpyrazine phosphate and borneol in mouse plasma and brain tissue after oral administration of the fufang tetramethylpyrazine phosphate tablets.
Qi-neng, P; Yan-Yu, X; Zhi-peng, C,
)
0.35
"Brain pharmacokinetic behaviors of tetramethylpyrazine (TMP) following intranasal (i."( Brain pharmacokinetics of tetramethylpyrazine after intranasal and intravenous administration in awake rats.
Abe, Y; Feng, J; Feng, Y; Li, F; Zhao, Y, 2009
)
0.93
" To study its pharmacokinetic characteristics, a simple and rapid HPLC-UV method was developed and validated to quantitatively determine TBN concentration in rat plasma."( Pharmacokinetic study of a novel stroke therapeutic, 2-[[(1,1-dimethylethyl)oxidoimino]methyl]-3,5,6-trimethylpyrazine, by a simple HPLC-UV method in rats.
Chen, H; Jiang, J; Li, S; Wang, X; Wang, Y; Wu, J, 2011
)
0.37
" Pharmacokinetic software 3p97 was applied to calculate pharmacokinetic parameters and the area under the drug concentration-time curve (AUC) in various tissues."( Pharmacokinetics of ligustrazine ethosome patch in rats and anti-myocardial ischemia and anti-ischemic reperfusion injury effect.
He, Z; Liu, H; Liu, J; Liu, X; Zeng, Z; Zhou, W, 2011
)
0.37
"In compatibility with FA, AUC(0-t), Cmax and Tmax showed no significant difference with the single administration of TMP, but t(1/2) and MRT,, were obviously longer than the single administration."( [Effect of different compatibility of tetramethylpyrazine on its pharmacokinetics in vivo].
Chen, G; Feng, B; Xu, X; Zhang, J, 2012
)
0.65
" The single and multiple-dose pharmacokinetic profiles of TMP administrated by TMP transdermal patch were characterized in healthy volunteers using an in vivo, randomized, open-label, two-way crossover design."( Single- and multiple-dose pharmacokinetics of a novel tetramethylpyrazine reservoir-type transdermal patch versus tetramethylpyrazine phosphate oral tablets in healthy normal volunteers, and in vitro/in vivo correlation.
Shen, T; Weng, W; Xu, H; Zhang, J, 2013
)
0.64
"To verify established the total quantum statistic moments model with astragaloside IV, paeoniflorin, tetramethylpyrazine in Buyanghuanwu injection, in order to establish a pharmacokinetic experimental method with multi-component traditional Chinese medicine (TCM) compound system."( [Experimental studies on pharmacokinetics of three components in Buyanghuanwu injection on base of total quantum statistical moment].
Deng, KW; He, FY; He, QP; Li, B; Liu, W; Liu, WL; Shi, JL; Wu, Y, 2013
)
0.61
" The pharmacokinetic parameters for single component were dealt with DAS and the total quantum statistical moment (TQSM) parameters were calculated using formulations."( [Experimental studies on pharmacokinetics of three components in Buyanghuanwu injection on base of total quantum statistical moment].
Deng, KW; He, FY; He, QP; Li, B; Liu, W; Liu, WL; Shi, JL; Wu, Y, 2013
)
0.39
" The TQSM pharmacokinetic parameters of the three components in Buyanghuanwu injection showed that AUC(t), MRT(t), VRT(t), CL(t), V(t), were (119."( [Experimental studies on pharmacokinetics of three components in Buyanghuanwu injection on base of total quantum statistical moment].
Deng, KW; He, FY; He, QP; Li, B; Liu, W; Liu, WL; Shi, JL; Wu, Y, 2013
)
0.39
"The TQSM can be used to study pharmacokinetic parameters of multi-component TCM compound, because the method can characterize the pharmacokinetic regularity of quantum-time change in a multi-component system."( [Experimental studies on pharmacokinetics of three components in Buyanghuanwu injection on base of total quantum statistical moment].
Deng, KW; He, FY; He, QP; Li, B; Liu, W; Liu, WL; Shi, JL; Wu, Y, 2013
)
0.39
"Pharmacokinetics of drug may be altered by abnormal physiological functions in illness, which will affect its pharmacodynamic efficacy in turn."( Pharmacokinetic variations of tetramethylpyrazine phosphate after oral administration in hepatic precancerous mice and its hepatoprotective effects.
Cai, D; Feng, L; Jiao, Y; Liu, X; Mao, W; Wang, X; Wang, Y; Zhang, D; Zhang, J; Zhao, X, 2014
)
0.69
"To assess the preventive effects of tetramethylpyrazine (TMPZ) phosphate on hepatocarcinogenesis and its pharmacokinetic differentiations in model mice."( Pharmacokinetic variations of tetramethylpyrazine phosphate after oral administration in hepatic precancerous mice and its hepatoprotective effects.
Cai, D; Feng, L; Jiao, Y; Liu, X; Mao, W; Wang, X; Wang, Y; Zhang, D; Zhang, J; Zhao, X, 2014
)
0.97
" Pharmacokinetic variations of TMPZ between control and model mice were measured for single oral administration."( Pharmacokinetic variations of tetramethylpyrazine phosphate after oral administration in hepatic precancerous mice and its hepatoprotective effects.
Cai, D; Feng, L; Jiao, Y; Liu, X; Mao, W; Wang, X; Wang, Y; Zhang, D; Zhang, J; Zhao, X, 2014
)
0.69
" In pharmacokinetic study, values of AUC and Tmax of TMPZ became significantly greater with increase of doses in both control and model mice, which elucidated the absorption was enhanced and delayed; meanwhile, its elimination was not affected markedly."( Pharmacokinetic variations of tetramethylpyrazine phosphate after oral administration in hepatic precancerous mice and its hepatoprotective effects.
Cai, D; Feng, L; Jiao, Y; Liu, X; Mao, W; Wang, X; Wang, Y; Zhang, D; Zhang, J; Zhao, X, 2014
)
0.69
" In addition, a simple and rapid HPLC-UV method was developed and validated to study the pharmacokinetic characteristics of the compound."( A new ligustrazine derivative--pharmacokinetic evaluation and antitumor activity by suppression of NF-kappaB/p65 and COX-2 expression in S180 mice.
Cheng, Y; Guo, J; Lei, H; Li, Q; Pang, D; Wang, P; Xu, K; Zhang, H; Zhang, Y, 2013
)
0.39
" The validated method was successfully applied in a pharmacokinetic study in rats after intravenous administration of Shenxiong glucose injection."( A UPLC-MS/MS method for simultaneous determination of danshensu, protocatechuic aldehyde, rosmarinic acid, and ligustrazine in rat plasma, and its application to pharmacokinetic studies of Shenxiong glucose injection in rats.
Gong, Z; Huang, Y; Lan, Y; Liu, Y; Lu, Y; Wang, A; Wang, Y; Xie, Y; Zheng, L, 2015
)
0.42
" Chf197 is one of the structurally modified ligustrazine derivatives in a purpose of overcoming the rapid metabolism and short half-life of original."( Pharmacokinetics and metabolism of Chf197, a ligustrazine derivative, in rats.
Chen, H; Guo, R; Kong, X; Li, W; Liu, H; Liu, X; Tang, M; Wei, C; Wei, X, 2015
)
0.42
" Gastrodin (GAS), a bioactive component of tianma, its pharmacokinetic (PK) behavior significantly changed after oral administration of DCXDCP compared with the extract of tianma."( Pharmacokinetic comparative study of gastrodin after oral administration of Gastrodia elata Bl. extract and its compatibility with the different indigents of Ligusticum chuanxiong Hort. to rats.
Hu, PY; Liu, D; Wu, B; Yang, M; Yue, PF; Zhang, GS; Zheng, Q, 2016
)
0.43
" The pharmacokinetic parameters of TMP were investigated in brain microdialysates after oral and intravenous administration of TMP (4 mg/kg) to rats in the absence and presence of FA (5 mg/kg)."( Effect of ferulic acid on the brain pharmacokinetics of tetramethylpyrazine in conscious rats.
Deng, X; Liao, F; Liao, W; Meng, Y; Wang, L; Wu, Y; Yu, J; Zheng, H, 2017
)
0.7
"The mechanisms of action of an herb-pair, Chuanxiong-Chishao, were investigated using the network pharmacological and pharmacodynamic strategies involving computational drug target prediction and network analysis, and experimental validation."( Synergistic effects of Chuanxiong-Chishao herb-pair on promoting angiogenesis at network pharmacological and pharmacodynamic levels.
Chen, KJ; Cong, WH; Guo, G; Hu, YJ; Lee, SM; Liao, QW; Wang, Y; Xin, QQ; Yang, BR, 2017
)
0.46
" The pharmacokinetic and brain distribution were studied in SD mice administered intravenously with NMD/TMP-NPs in comparison with NMD-suspension, NMD/TMP-suspension and NMD-NPs, (NMD-NPs+TMP)-suspension."( [Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles].
He, WJ; He, XW; Hong, Q; Liang, J; Zhu, FJ, 2016
)
0.43
"In BYHWI, five candidate Q-marker pharmacokinetic profiles were singly fixed to two compartmental models in rat using classical compartmental analysis, but there were tremendous differences among which the candidate parameters were fluctuated from nearly 3552 folds to equivalency."( Application of TQSM polypharmacokinetics and its similarity approach to ascertain Q-marker by analyses of transitivity in vivo of five candidates in Buyanghuanwu injection.
Deng, KW; He, FY; Liao, Q; Liu, WL; Tang, Y; Xiao, MF; Yang, YT; Zhang, YT; Zhou, YQ, 2018
)
0.48
" It is feasible for Q-marker in CMMs to screen on the comparison of single pharmacokinetic behavior and bioavailability to the total quanta."( Application of TQSM polypharmacokinetics and its similarity approach to ascertain Q-marker by analyses of transitivity in vivo of five candidates in Buyanghuanwu injection.
Deng, KW; He, FY; Liao, Q; Liu, WL; Tang, Y; Xiao, MF; Yang, YT; Zhang, YT; Zhou, YQ, 2018
)
0.48
"To assess and compare the pharmacokinetic characteristics and bioequivalence of two tetramethylpyrazine phosphate (TMPP) tablets in healthy Chinese male subjects."( Pharmacokinetics and bioequivalence study of tetramethylpyrazine phosphate tablets after single-dose administration in healthy Chinese male subjects
.
Guo, R; Li, H; Wang, B; Yuan, G, 2018
)
0.97
"0 was used to calculate the pharmacokinetic parameters and assess bioequivalence of the two formulations."( Pharmacokinetics and bioequivalence study of tetramethylpyrazine phosphate tablets after single-dose administration in healthy Chinese male subjects
.
Guo, R; Li, H; Wang, B; Yuan, G, 2018
)
0.74
" The main pharmacokinetic parameters of test and reference formulations were as follows: T1/2 was (1."( Pharmacokinetics and bioequivalence study of tetramethylpyrazine phosphate tablets after single-dose administration in healthy Chinese male subjects
.
Guo, R; Li, H; Wang, B; Yuan, G, 2018
)
0.74
" Pharmacokinetic assessment of TMP, FA, gastrodin or gastrodigenin in blood or brain interstitial fluid (BIF) has been reported in healthy animals."( Pharmacokinetic comparative study of tetramethylpyrazine and ferulic acid and their compatibility with different concentration of gastrodin and gastrodigenin on blood-stasis migraine model by blood-brain microdialysis method.
Cheng, H; Guo, S; Ke, G; Liu, M; Mao, Y; Mi, Y; Wang, M; Wei, P, 2020
)
0.83
" Pharmacokinetic parameters were determined using the blood-brain microdialysis in combination with the high-performance liquid chromatography method."( Pharmacokinetic comparative study of GAS with different concentration of tetramethylpyrazine and ferulic acid on liver-yang hyperactivity migraine model by blood-brain microdialysis method.
Cheng, H; Li, S; Liu, M; Mi, Y; Wang, M, 2020
)
0.79
"The present study investigated the effects of ligustrazine hydrochloride(LH)-Salviae Miltiorrhizae Radix et Rhizoma(SM) before and after compatibility on the pharmacokinetics of acute myocardial ischemia(AMI) rats and revealed the mechanism of pharmacokinetic changes from the perspective of metabolic enzymes."( [Effects and correlation of ligustrazine hydrochloride-Salviae Miltiorrhizae Radix et Rhizoma compatibility on pharmacokinetics and CYP450 enzyme].
Li, R; Liu, CH; Liu, T; Lu, DY; Sun, J; Zhang, JY; Zheng, L, 2022
)
0.72

Compound-Compound Interactions

The purpose of this study was to detect the changes of P-Glycoprotein (P-GP) expression in rat brain microvessel endothelial cell line RBE4 after the action of Tetramethylpyrazine (TMP) on Carbamazepine (CBZ) The aim was to clarify the potential mechanism of TMP combined with CBZ against intractable epilepsy drug resistance.

ExcerptReferenceRelevance
"To assess the efficacy of Ligustrazine in combination with propranolol in the prevention of recurrent esophageal varices bleeding following liver cirrhosis, and its act mechanism."( [A randomized controlled study of ligustrazine in combination with propranolol for prevention of recurrent esophageal varices bleeding].
Chen, D; Li, X; Zou, J, 2000
)
0.31
"To observe the effect of inhalation of aerosolized perfluorocarbon combined with tetramethylpyrazine on the hemodynamics and histopathology in a porcine model of acute lung injury."( [Inhalation of aerosolized perfluorocarbon combined with tetramethylpyrazine ameliorates hemodynamics and pulmonary histopathology in a porcine model of acute lung injury].
Li, YL; Peng, XM; Shuai, B; Wang, HD; Wang, YP; Wang, ZH; Xie, JH, 2011
)
0.84
"To investigate the effect of small interfering RNA (siRNA) silencing Apollon gene combined with tetramethylpyrazine (TMP) on the proliferation and apoptosis of human chronic myeloid leukemia cell line K562."( [Effect of Apollon siRNA combined with tetramethylpyrazine on proliferation and apoptosis of leukemia K562 cells].
Jia, XH; Li, JC; Xiao, FF, 2014
)
0.89
"Apollon siRNA can significantly inhibit the proliferation and promote the apoptosis of K562 cells, and the addition of TMP can further increase the proliferation inhibition rate and apoptosis rate, suggesting that siRNA technology combined with drugs has a significant potential value in the treatment of leukemia."( [Effect of Apollon siRNA combined with tetramethylpyrazine on proliferation and apoptosis of leukemia K562 cells].
Jia, XH; Li, JC; Xiao, FF, 2014
)
0.67
"BACKGROUND This study aimed to explore the therapeutic effect of external application of ligustrazine combined with holistic nursing on pressure sores, as well as the underlying mechanism."( Therapeutic Effect of External Application of Ligustrazine Combined with Holistic Nursing on Pressure Sores.
Gong, F; Han, L; Niu, J, 2016
)
0.43
"The results showed that TMP combined with ucMSCs treatment significantly decreased the neurological deficit score, as well as the cerebral infarct ratio (from 16."( The Effect of Umbilical Cord Mesenchymal Stem Cells Combined with Tetramethylpyrazine Therapy on Ischemic Brain Injury: A Histological Study.
Cao, H; Cheng, Y; Ge, L; Xu, M; Zhang, J, 2020
)
0.8
"These data suggest that ucMSCs combined with TMP are able to exert therapeutic effects following ischemic injury by improving neurogenesis, inhibiting inflammation, and ameliorating histological damage."( The Effect of Umbilical Cord Mesenchymal Stem Cells Combined with Tetramethylpyrazine Therapy on Ischemic Brain Injury: A Histological Study.
Cao, H; Cheng, Y; Ge, L; Xu, M; Zhang, J, 2020
)
0.8
"Currently, it is unclear whether the salviae miltiorrhizae (Danshen Salvia) and ligustrazine hydrochloride (Chuanxiong Chuanxiong) (SMLH) injection combined with mecobalamin can improve diabetic peripheral neuropathy (DPN)."( Salviae miltiorrhizae and ligustrazine hydrochloride injection combined with mecobalamin for treating diabetic peripheral neuropathy: A protocol for systematic review and meta-analysis.
Deng, Z; Fan, Y; Liu, M; Wang, M, 2021
)
0.62
" Each database was searched up to 2020 to identify randomized controlled trials on DPN treated with SMLH injection combined with mecobalamin."( Salviae miltiorrhizae and ligustrazine hydrochloride injection combined with mecobalamin for treating diabetic peripheral neuropathy: A protocol for systematic review and meta-analysis.
Deng, Z; Fan, Y; Liu, M; Wang, M, 2021
)
0.62
"SMLH injection combined with mecobalamin can improve DPN, compared with mecobalamin alone."( Salviae miltiorrhizae and ligustrazine hydrochloride injection combined with mecobalamin for treating diabetic peripheral neuropathy: A protocol for systematic review and meta-analysis.
Deng, Z; Fan, Y; Liu, M; Wang, M, 2021
)
0.62
"The purpose of this study was to detect the changes of P-Glycoprotein (P-GP) expression in rat brain microvessel endothelial cell line RBE4 after the action of Tetramethylpyrazine (TMP) on Carbamazepine (CBZ), so as to clarify the potential mechanism of TMP combined with CBZ against intractable epilepsy drug resistance."( Study on the reversal of epileptic drug resistance by tetramethylpyrazine in combination with carbamazepine through modulation of P-Glycoprotein expression in rat brain microvessel endothelial cell.
Deng, Y; Li, Y; Liu, J; Liu, W; Qian, X; Wang, J; Xiao, G; Yan, J; Ye, J; Zhong, N, 2023
)
1.36

Bioavailability

Ligustrazine (or Tetramethylpyrazine, TMP) is an active pharmaceutical ingredient that faces the challenges of bitter taste and low oral bioavailability by the commercial phosphate salt (TMP-Pho) Borneol and verapamil did enhance the bioavailability of tetramethyl pyrazine phosphate after oral administration in rats.

ExcerptReferenceRelevance
" It demonstrated that the absorption of TMP of LW-SM decoction was slower and the bioavailability of TMP of LW-SM decoction reduced."( [Influence of combined Salvia miltiorrhiza and Ligusticum wallichii on pharmacokinetics of tetramethylpyrazine in rats].
Huang, X; Ren, P; Xia, T, 1994
)
0.51
" There were no significant differences in the peritoneal fluid absorption rate among the 3 dialysis groups."( [Experimental study on effect of ligustrazine on peritoneal ultrafiltrative function in rats].
Yang, Q; Yang, X; Ye, R, 2000
)
0.31
" Borneol and verapamil did enhance the bioavailability of tetramethylpyrazine phosphate after oral administration in rats."( [The enhancing effect of borneol on the absorption of tetramethylpyrazine].
Chen, HX; Chen, ZP; Ping, QN; Xiao, YY, 2009
)
0.85
" And the absolute bioavailability was 36."( Pharmacokinetic study of a novel stroke therapeutic, 2-[[(1,1-dimethylethyl)oxidoimino]methyl]-3,5,6-trimethylpyrazine, by a simple HPLC-UV method in rats.
Chen, H; Jiang, J; Li, S; Wang, X; Wang, Y; Wu, J, 2011
)
0.37
" The pharmacokinetic results revealed that the relative bioavailability was 209."( Preparation of a ligustrazine ethosome patch and its evaluation in vitro and in vivo.
Ding, C; He, Z; Huang, G; Liu, H; Liu, J; Liu, X; Zhou, L; Zhou, W, 2011
)
0.37
" The relative bioavailability of OTSP was studied in six beagle dogs after oral administration using a commercial TMPP tablets as a reference."( Preparation and pharmacokinetics in beagle dogs of once-a-day tetramethylpyrazine phosphate sustained-release pellets.
Hongying, L; Jiangxiu, N; Qineng, P; Yanyu, X; Zhigui, S, 2012
)
0.62
" In the pharmacokinetic study, the relative bioavailability of TMP-O/W-EVA-TTS was 350."( Microemulsion-based novel transdermal delivery system of tetramethylpyrazine: preparation and evaluation in vitro and in vivo.
Chen, ZQ; Feng, NP; Ji, L; Liu, Y; Wang, H; Zhang, YT; Zhao, JH, 2011
)
0.61
"6-fold compared with that of the commercially available ligustrazine injection (LI), suggesting enhanced bioavailability from the lipid-based emulsion."( Development of ligustrazine-loaded lipid emulsion: formulation optimization, characterization and biodistribution.
Kim, JO; Li, G; Marasini, N; Quan, Q; Wei, L; Yong, CS, 2012
)
0.38
" The Q-marker was ascertained with transitive similarity and bioavailability in polypharmacokinetics."( Application of TQSM polypharmacokinetics and its similarity approach to ascertain Q-marker by analyses of transitivity in vivo of five candidates in Buyanghuanwu injection.
Deng, KW; He, FY; Liao, Q; Liu, WL; Tang, Y; Xiao, MF; Yang, YT; Zhang, YT; Zhou, YQ, 2018
)
0.48
"The results represented that the optimum Q-marker in BYHWI is astragaloside Ⅳ, whose transitivity in vivo similarity was close to the behavior of polypharmacokinetics with maximum bioavailability to the total quanta."( Application of TQSM polypharmacokinetics and its similarity approach to ascertain Q-marker by analyses of transitivity in vivo of five candidates in Buyanghuanwu injection.
Deng, KW; He, FY; Liao, Q; Liu, WL; Tang, Y; Xiao, MF; Yang, YT; Zhang, YT; Zhou, YQ, 2018
)
0.48
" The relative bioavailability of TMPP tablets was 102."( Pharmacokinetics and bioequivalence study of tetramethylpyrazine phosphate tablets after single-dose administration in healthy Chinese male subjects
.
Guo, R; Li, H; Wang, B; Yuan, G, 2018
)
0.74
"Ligustrazine (or Tetramethylpyrazine, TMP) is an active pharmaceutical ingredient that faces the challenges of bitter taste and low oral bioavailability by the commercial phosphate salt (TMP-Pho)."( Simultaneous taste-masking and oral bioavailability enhancement of Ligustrazine by forming sweet salts.
He, X; Hu, S; Li, Q; Sun, CC; Wang, C; Zhao, X, 2020
)
0.9
" The above results indicated that TMP had a higher bioavailability of hepatoprotection when encapsulation of LCE-PLA was applied."( Fabrication of Ligusticum chuanxiong polylactic acid microspheres: A promising way to enhance the hepatoprotective effect on bioactive ingredients.
Chen, J; Ge, H; Lin, P; Luo, T; Miao, S; Xiao, J; Yan, Z, 2020
)
0.56
" The results of in vivo pharmacokinetic studies show that TAT-TMP-NPs improves the bioavailability of TMP."( TAT-modified serum albumin nanoparticles for sustained-release of tetramethylpyrazine and improved targeting to spinal cord injury.
Du, X; Li, C; Li, J; Li, T; Lin, Y; Liu, Z; Wan, Y; Wei, J; Zhong, Z; Zhou, M, 2021
)
0.86
" TAT-TMP-NPs may overcome the poor water solubility and low bioavailability of TMP, showing promise for the clinical treatment of SCI."( TAT-modified tetramethylpyrazine-loaded nanoparticles for targeted treatment of spinal cord injury.
Bai, X; Du, X; Li, C; Li, J; Lin, Y; Liu, Z; Wan, Y; Wei, J; Zhong, Z; Zhou, M, 2021
)
0.99
" Importantly, cocrystallization simultaneously improves bioavailability of both parent drugs."( Simultaneous improvement of physical stability, dissolution, bioavailability, and antithrombus efficacy of Aspirin and Ligustrazine through cocrystallization.
Hao, Y; He, X; Sun, CC; Wang, C; Wang, K; Zhao, X, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" Three dosage levels (1."( [Effects of scoparone on hemodynamics in anesthetized rabbits].
Huang, JC; Sun, AX; Wang, RX; Wang, XR, 1993
)
0.29
" In an attempt to prepare a lung targeting dosage form, ligustrazine hydrochloride gelatin microspheres (LTH-GMS) were prepared by the method of emulsion process, using 2:1 as the weight ratio of LTH to gelatin."( [Studies on gelatin microsphere loaded ligustrazine hydrochloride for lung targeting].
Deng, XX; Lu, B; Yang, H; Zeng, FB, 1996
)
0.29
" SM and TP could prolong the multiplication time of fibroblasts and this effect was correlated postively with the dosage of drug."( [The influence of salvia miltiorrhiza and tetramethyl pyrazine on DNA content of cicatricial fibroblasts and its cellular cycle].
Guan, W; Shang, Q; Zhang, D, 1998
)
0.3
" Different dosage of TMP, RSM and norepinephrine (NE) were used to study their effects on the collagen synthesis and proliferation of cultured cardiac Fbs."( [Effects of tetramethylpyrazine and radix salviae miltiorrhizae on collagen synthesis and proliferation of cardiac fibroblasts].
Song, D; Su, H; Wu, M, 1998
)
0.68
"Compared with the control group, moderate or high dosage TMP and RSM could significantly inhibit the collagen synthesis and the proliferation of cultured cardiac Fbs."( [Effects of tetramethylpyrazine and radix salviae miltiorrhizae on collagen synthesis and proliferation of cardiac fibroblasts].
Song, D; Su, H; Wu, M, 1998
)
0.68
"To compare clinical curative effect of acute ischemic cerebrovascular diseases (ICVD) treated with different dosage of ligustrazine and to observe the effect of ligustrazine on hemorrheology."( [Observation on curative effect of acute ischemic cerebrovascular disease treated with different dosage of ligustrazine].
Cai, Y; Ren, M; Yang, R, 2000
)
0.31
" The dose-response relationship of liver injury induced by various doses of econazole was observed simultaneously from serum biochemical assay of SGOT and SGPT, and also from hepatohistological microscopic examination, by determination of the hepatoprotective effects of various concentrations of TMP on SGOT and SGPT elevation induced by a hepatotoxic dose of econazole (300 mg/kg)."( Hepatoprotective and therapeutic effects of tetramethylpyrazine on acute econazole-induced liver injury.
Lin, CC; Lin, SC; Liu, CF; Ng, LT, 2002
)
0.58
" Ligustrazine with the dosage of 80 mg twice a day was given to 25 patients in the treatment group by intravenous perfusion besides the medicine used in the control group."( [Effect of ligustrazine on proliferative glomerulonephritis].
Tang, X, 2003
)
0.32
" The dose-response curves for IATP in the absence and presence of 1 mM TMP showed that TMP (1 mM) shifted the concentration-response curve of IATP downward markedly and the two EC50 values were very close (75 vs."( Tetramethylpyrazine inhibits ATP-activated currents in rat dorsal root ganglion neurons.
Gao, Y; Li, GL; Liang, SD; Liu, HQ; Xu, CS; Zhou, T, 2005
)
1.77
"Ligustrazine could markedly tingle the spontaneous electrical activity of the muscle spindle, and it also showed a good dose-response relationship, while Salvia Miltiorrhiza and Safflower had no such excitative effect."( [Effects of three Chinese traditional drugs on afferent discharge from single muscle spindle in toads].
Fan, XL; Gao, YF, 2005
)
0.33
" The clinical condition scores, frequency of attacks and dosage of Terbutaline inhaled were scored and recorded on the first day of hospitalization (before treatment) and after treatment."( Effect of ligustrazine injection on levels of interleukin-4 and interferon-gamma in patients with bronchial asthma.
Che, XW; Wang, H; Wang, W; Zhang, Y, 2008
)
0.35
"Low dosage of TMP can reduced myocardial pathology injury, increased Ca(2+)-ATPase activity of myocardial mitochondria, improve cardiac function and [Ca2+]i in cardiocyte and antagonise calcium overload of rats with DHF."( [Studies on protection and mechanism of tetramethylpyrazine on myocardial injury of rats with DHF].
Fan, C; Liu, W; Zhang, X; Zhou, J, 2009
)
0.62
" At the same time, TMP (trade name: Chuanqing, containing 120 mg of TMP in a 2 mL ampoule) was given additionally to patients in Group B at the dosage of 240 mg/d by adding in 250 mL of normal saline via iv dripping."( [Effects of tetramethylpyrazine on fractalkine and tumor necrosis factor-alpha expression in patients with chronic pulmonary heart disease].
Dong, YQ; Li, L; Wang, LX, 2010
)
0.74
"98 μg min/mL) after the same dosage of intravenous administration (80 mg/kg)."( Pharmacokinetic study of a novel stroke therapeutic, 2-[[(1,1-dimethylethyl)oxidoimino]methyl]-3,5,6-trimethylpyrazine, by a simple HPLC-UV method in rats.
Chen, H; Jiang, J; Li, S; Wang, X; Wang, Y; Wu, J, 2011
)
0.37
" A different dosage of TMP was employed to stimulate the mouse microvascular cell line bEnd."( Tetramethylpyrazine promotes the proliferation and migration of brain endothelial cells.
Gao, F; Teng, F; Zhang, C; Zhang, M, 2014
)
1.85
" Rats were randomized into 4 groups: G1 (NS control group), G2 ("double-hit" group), G3 (low dosage TMP group) and G4 (high dosage TMP group)."( A modified "double-hit" induced acute lung injury model in rats and protective effects of tetramethylpyrazine on the injury via Rho/ROCK pathway.
Chen, Q; Dong, S; Li, J; Li, Y; Yang, X; Zhang, G; Zhang, Y; Zhao, S, 2015
)
0.64
"The optimal formulation composed with the dosage of P407,P188 and PEG-6000 were 18%,7% and 1%,respectively."( [Preparation of Salviae Miltiorrhiza and Ligustrazine Hydrochloride Nasal Thermosensitive in Situ Gel and Study on Characterization of Its Nasal Mucosal Permeability].
Gao, Q; Hao, WQ; Lin, Y; Yuan, X, 2016
)
0.43
" Considering the large dosage range of Lig used clinically and in animals, the future studies on the basis of animal renal histology are urgently needed to determine the optimal dosages to delay histological changes."( Protective effect and possible mechanisms of ligustrazine isolated from Ligusticum wallichii on nephropathy in rats with diabetes: A preclinical systematic review and meta-analysis.
Huang, YY; Pan, XD; Wang, ZH; Zheng, Q; Zhuang, Z, 2020
)
0.56
" In addition, the commonly used dosage forms of TMP include tablets, dropping pills, injections, etc."( TAT-modified serum albumin nanoparticles for sustained-release of tetramethylpyrazine and improved targeting to spinal cord injury.
Du, X; Li, C; Li, J; Li, T; Lin, Y; Liu, Z; Wan, Y; Wei, J; Zhong, Z; Zhou, M, 2021
)
0.86
" However, its clinical application is limited due to poor water solubility and insufficient spinal cord targeting through the traditional dosage forms."( TAT-modified tetramethylpyrazine-loaded nanoparticles for targeted treatment of spinal cord injury.
Bai, X; Du, X; Li, C; Li, J; Lin, Y; Liu, Z; Wan, Y; Wei, J; Zhong, Z; Zhou, M, 2021
)
0.99
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inhibitorAny substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
vasodilator agentA drug used to cause dilation of the blood vessels.
platelet aggregation inhibitorA drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyrazines
alkaloidAny of the naturally occurring, basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom, but also found in bacteria, fungi, and animals. By extension, certain neutral compounds biogenetically related to basic alkaloids are also classed as alkaloids. Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. Compounds in which the nitrogen is exocyclic (dopamine, mescaline, serotonin, etc.) are usually classed as amines rather than alkaloids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
tetramethylpyrazine degradation514

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
progesterone receptorHomo sapiens (human)Potency34.34130.000417.946075.1148AID1346795
retinoid X nuclear receptor alphaHomo sapiens (human)Potency43.61980.000817.505159.3239AID1159527
aryl hydrocarbon receptorHomo sapiens (human)Potency54.42730.000723.06741,258.9301AID743085
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
Thioredoxin reductase 1, cytoplasmicHomo sapiens (human)IC50 (µMol)200.00000.04322.26555.0000AID1628166; AID1628167; AID1628168
Thioredoxin reductase 3Homo sapiens (human)IC50 (µMol)200.00000.35003.11675.0000AID1628166; AID1628167; AID1628168
Thioredoxin reductase 2, mitochondrialHomo sapiens (human)IC50 (µMol)200.00000.35003.11675.0000AID1628166; AID1628167; AID1628168
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (33)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
mesoderm formationThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
signal transductionThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cell population proliferationThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cellular oxidant detoxificationThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cell redox homeostasisThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
spermatogenesisThioredoxin reductase 3Homo sapiens (human)
cell differentiationThioredoxin reductase 3Homo sapiens (human)
cell redox homeostasisThioredoxin reductase 3Homo sapiens (human)
cellular oxidant detoxificationThioredoxin reductase 3Homo sapiens (human)
response to oxygen radicalThioredoxin reductase 2, mitochondrialHomo sapiens (human)
response to xenobiotic stimulusThioredoxin reductase 2, mitochondrialHomo sapiens (human)
response to selenium ionThioredoxin reductase 2, mitochondrialHomo sapiens (human)
cell redox homeostasisThioredoxin reductase 2, mitochondrialHomo sapiens (human)
response to hyperoxiaThioredoxin reductase 2, mitochondrialHomo sapiens (human)
cellular oxidant detoxificationThioredoxin reductase 2, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
thioredoxin-disulfide reductase (NADPH) activityThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
protein bindingThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
identical protein bindingThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
NADPH peroxidase activityThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
FAD bindingThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
thioredoxin-disulfide reductase (NADPH) activityThioredoxin reductase 3Homo sapiens (human)
flavin adenine dinucleotide bindingThioredoxin reductase 3Homo sapiens (human)
thioredoxin-disulfide reductase (NADPH) activityThioredoxin reductase 2, mitochondrialHomo sapiens (human)
protein bindingThioredoxin reductase 2, mitochondrialHomo sapiens (human)
protein homodimerization activityThioredoxin reductase 2, mitochondrialHomo sapiens (human)
protein-containing complex bindingThioredoxin reductase 2, mitochondrialHomo sapiens (human)
flavin adenine dinucleotide bindingThioredoxin reductase 2, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
fibrillar centerThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
nucleoplasmThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cytosolThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
extracellular exosomeThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
mitochondrionThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cytosolThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cytoplasmThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
nucleoplasmThioredoxin reductase 3Homo sapiens (human)
endoplasmic reticulumThioredoxin reductase 3Homo sapiens (human)
cytosolThioredoxin reductase 3Homo sapiens (human)
mitochondrionThioredoxin reductase 3Homo sapiens (human)
cytoplasmThioredoxin reductase 3Homo sapiens (human)
cytosolThioredoxin reductase 3Homo sapiens (human)
mitochondrionThioredoxin reductase 2, mitochondrialHomo sapiens (human)
mitochondrial matrixThioredoxin reductase 2, mitochondrialHomo sapiens (human)
cytosolThioredoxin reductase 2, mitochondrialHomo sapiens (human)
axonThioredoxin reductase 2, mitochondrialHomo sapiens (human)
dendriteThioredoxin reductase 2, mitochondrialHomo sapiens (human)
neuronal cell bodyThioredoxin reductase 2, mitochondrialHomo sapiens (human)
cytoplasmThioredoxin reductase 2, mitochondrialHomo sapiens (human)
mitochondrionThioredoxin reductase 2, mitochondrialHomo sapiens (human)
cytosolThioredoxin reductase 2, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (124)

Assay IDTitleYearJournalArticle
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1277571Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as locomotor function recovery at 200 mg/kg, ip measured during 3 to 28 days in presence of 25 umol/kg of HO-1 inhibitor ZnPP2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277604Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as increase in superoxide dismutase activity at 200 mg/kg, ip in presence of Akt inhibitor LY2940022016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277573Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in Evans blue leakage in spinal cord tissue at 200 mg/kg, ip after 24 hrs2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1353598Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Mar-10, Volume: 147Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives.
AID1609879Neuroprotective activity against H2O2-induced cell damage in human SH-SY5Y cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Design, synthesis and biological evaluation of cinnamic acid derivatives with synergetic neuroprotection and angiogenesis effect.
AID1353589Protection against H2O2-induced damage in HUVEC2018European journal of medicinal chemistry, Mar-10, Volume: 147Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives.
AID1277587Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as accumulation at G0/G1 phase at 200 mg/kg, ip by TUNEL staining-based flow cytometric analysis (Rvb = 34.1 %)2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID295433Inhibition of ADP-induced platelet aggregation in rabbit plasma at 200 uM2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Design, synthesis, and biological activities of novel Ligustrazine derivatives.
AID1277577Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in Evans blue leakage in spinal cord tissue at 200 mg/kg, ip after 48 hrs in presence of Akt inhibitor LY2940022016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277608Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as increase in Akt phosphorylation at 200 mg/kg, ip by Western blot analysis2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID665464Antioxidant activity assessed as peroxynitrite radical-scavenging activity at 1 to 1000 uM by SIN-1 based chemiluminescence assay2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Novel multi-functional nitrones for treatment of ischemic stroke.
AID1600985Anticoagulant activity in rabbit platelet poor plasma assessed as prothrombin time at 100 uM incubated for 3 mins by coagulometric analysis (Rvb = 4.32 +/- 0.28 sec)2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Hybrid molecules of scutellarein and tertramethylpyrazine's active metabolites for ischemic stroke.
AID1277582Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in TNF-alpha levels in spinal cord tissue at 200 mg/kg, ip by ELISA in presence of 25 umol/kg of HO-1 inhibitor ZnPP2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277590Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in activated caspase-3 level at 200 mg/kg, ip2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1353609Neuroprotection against CoCl2-induced toxicity in rat PC12 cells2018European journal of medicinal chemistry, Mar-10, Volume: 147Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives.
AID349370Neuroprotective effect against middle cerebral artery occlusion-induced focal cerebral ischemia in Sprague-Dawley rat assessed as reduction in infarct area at 50 mg/kg, ip administered 1 hr after MCA occlusion measured after 24 hrs of reperfusion by TTC s2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke.
AID665465Antioxidant activity assessed as DPPH radical-scavenging activity at 0.5 to 4 mM by spectrophotometry2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Novel multi-functional nitrones for treatment of ischemic stroke.
AID1353602Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Mar-10, Volume: 147Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives.
AID1277584Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in IL-18 levels in spinal cord tissue at 200 mg/kg, ip by ELISA2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1628168Inhibition of thioredoxin reductase in human A549/CDDP cells by DTNB dye based microplate spectrophotometry2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of New Monocarbonyl Ligustrazine-Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer.
AID1277603Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as increase in superoxide dismutase activity at 200 mg/kg, ip in presence of 25 umol/kg of HO-1 inhibitor ZnPP2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1764211Antiproliferation activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents.
AID1455332Antiproliferative activity against human K562 cells after 72 hrs in presence of piperlongumine by MTT assay2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Novel Ligustrazine-Based Analogs of Piperlongumine Potently Suppress Proliferation and Metastasis of Colorectal Cancer Cells in Vitro and in Vivo.
AID1277589Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as accumulation at G0/G1 phase at 200 mg/kg, ip by TUNEL staining-based flow cytometric analysis in presence of Akt inhibitor LY294002 (Rvb = 34.1 %)2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1353600Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Mar-10, Volume: 147Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives.
AID1277579Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in IL1-beta levels in spinal cord tissue at 200 mg/kg, ip by ELISA in presence of 25 umol/kg of HO-1 inhibitor ZnPP2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1628166Inhibition of thioredoxin reductase (unknown origin) after 2 hrs by DTNB dye based microplate spectrophotometry2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of New Monocarbonyl Ligustrazine-Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer.
AID1277606Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as increase in HO-1 mRNA expression at 200 mg/kg, ip by real time PCR method in presence of 25 umol/kg of HO-1 inhibitor ZnPP2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1764214Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents.
AID1277600Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as increase in glutathione level at 200 mg/kg, ip by reduced glutathione assay in presence of 25 umol/kg of HO-1 inhibitor ZnPP2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277601Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as increase in glutathione level at 200 mg/kg, ip by reduced glutathione assay in presence of Akt inhibitor LY2940022016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277578Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in IL1-beta levels in spinal cord tissue at 200 mg/kg, ip by ELISA2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1628159Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of New Monocarbonyl Ligustrazine-Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer.
AID1353601Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Mar-10, Volume: 147Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives.
AID1628158Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of New Monocarbonyl Ligustrazine-Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer.
AID1277612Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as increase in Nrf2 mRNA expression at 200 mg/kg, ip by real time PCR method in presence of 25 umol/kg of HO-1 inhibitor ZnPP2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1353587Protection against H2O2-induced damage in human ECV304 cells preincubated for 24 hrs followed by H2O2 addition and measured after 12 hrs by MTT assay2018European journal of medicinal chemistry, Mar-10, Volume: 147Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives.
AID1600986Anticoagulant activity in rabbit platelet poor plasma assessed as fibrinogen level at 100 uM incubated for 3 mins by coagulometric analysis (Rvb = 14.24 +/- 0.67 g/l)2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Hybrid molecules of scutellarein and tertramethylpyrazine's active metabolites for ischemic stroke.
AID626515Protection against H2O2-induced toxicity in human ECV304 cells assessed as proliferation rate at 50 uM pretreated for 24 hrs before H2O2 challenge measured after 12 hrs by MTT assay2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents.
AID1353610Neuroprotection against CoCl2-induced toxicity in rat PC12 cells preincubated for 36 hrs followed by CoCl2 addition measured after 12 hrs by MTT assay2018European journal of medicinal chemistry, Mar-10, Volume: 147Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives.
AID1277593Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in activated caspase-9 level at 200 mg/kg, ip2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID349367Antithrombotic activity in Sprague-Dawley rat venous thrombus model assessed as inhibition of thrombus formation at 2 mg/kg, iv administered 2 hrs after ligation measured after 24 hrs relative to control2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke.
AID349365Inhibition of ADP-induced New Zealand rabbit platelet aggregation at 2 mM treated for 1 min prior to ADP challenge by turbidimetric method relative to control2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke.
AID1277597Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in thiobarbituric acid reactive substances level at 200 mg/kg, ip by malondialdehyde assay in presence of 25 umol/kg of HO-1 inhibitor ZnPP2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1600980Solubility in water2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Hybrid molecules of scutellarein and tertramethylpyrazine's active metabolites for ischemic stroke.
AID1609880Neuroprotective activity against H2O2-induced cell damage in human HBMEC2 cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Design, synthesis and biological evaluation of cinnamic acid derivatives with synergetic neuroprotection and angiogenesis effect.
AID1277594Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in activated caspase-9 level at 200 mg/kg, ip in presence of 25 umol/kg of HO-1 inhibitor ZnPP2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1353590Vasodilatory activity in Sprague-Dawley rat thoracic aorta rings assessed as reduction in KCl-induced contraction2018European journal of medicinal chemistry, Mar-10, Volume: 147Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives.
AID1277583Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in TNF-alpha levels in spinal cord tissue at 200 mg/kg, ip by ELISA in presence of Akt inhibitor LY2940022016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1600984Anticoagulant activity in rabbit platelet poor plasma assessed as activated partial thromboplastin time at 100 uM incubated for 3 mins by coagulometric analysis (Rvb = 19.13 +/- 0.54 sec)2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Hybrid molecules of scutellarein and tertramethylpyrazine's active metabolites for ischemic stroke.
AID349359Antioxidant activity assessed as inhibition of ROS-induced linoleic acid peroxidation at 1 mM after 15 mins at 100 degC by modified TBARS assay relative to control2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke.
AID1277602Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as increase in superoxide dismutase activity at 200 mg/kg, ip2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277598Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in thiobarbituric acid reactive substances level at 200 mg/kg, ip by malondialdehyde assay in presence of Akt inhibitor LY2940022016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1353585Protection against H2O2-induced damage in HUVEC preincubated for 0.5 hrs followed by H2O2 addition and measured after 12 hrs2018European journal of medicinal chemistry, Mar-10, Volume: 147Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives.
AID349368Antithrombotic activity in rat venous thrombosis model assessed as inhibition of thrombus formation at 1.2 mg/kg2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke.
AID1277596Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in thiobarbituric acid reactive substances level at 200 mg/kg, ip by malondialdehyde assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1600983Anticoagulant activity in rabbit platelet poor plasma assessed as thrombin time at 100 uM incubated for 3 mins by coagulometric analysis (Rvb = 12.58 +/- 0.76 sec)2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Hybrid molecules of scutellarein and tertramethylpyrazine's active metabolites for ischemic stroke.
AID1277581Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in TNF-alpha levels in spinal cord tissue at 200 mg/kg, ip by ELISA2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277615Induction of Nrf2 binding to HO-1 promoter in Sprague-Dawley rat model of spinal cord injury at 200 mg/kg, ip by chromatin immunoprecipitation assay in presence of 25 umol/kg of HO-1 inhibitor ZnPP2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277585Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in IL-18 levels in spinal cord tissue at 200 mg/kg, ip by ELISA in presence of 25 umol/kg of HO-1 inhibitor ZnPP2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID665456Neuroprotective activity against t-BHP-induced rat cerebellar granule neuronal damage at 1000 uM preincubated for 30 mins prior t-BHP challenge measured after 4 hrs by MTT assay (Rvb = 49.4%)2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Novel multi-functional nitrones for treatment of ischemic stroke.
AID1277595Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in activated caspase-9 level at 200 mg/kg, ip in presence of Akt inhibitor LY2940022016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID626518Protection against H2O2-induced toxicity in human ECV304 cells assessed as proliferation rate pretreated for 24 hrs before H2O2 challenge measured after 12 hrs by MTT assay2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents.
AID233351Evaluated for its olfactory detection threshold value and indicates quantitative measure of odour impression; No threshold value.2001Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17
Prediction of the aroma quality and the threshold values of some pyrazines using artificial neural networks.
AID626514Protection against H2O2-induced toxicity in human ECV304 cells assessed as proliferation rate at 100 uM pretreated for 24 hrs before H2O2 challenge measured after 12 hrs by MTT assay2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents.
AID1277599Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as increase in glutathione level at 200 mg/kg, ip by reduced glutathione assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID349361Neuroprotective effect against H202-induced Sprague-Dawley rat cortical neuron injury assessed as cell viability up to 1 mM treated 30 mins before H202 challenge measured after 24 hrs by MTT assay2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke.
AID1764212Antiproliferation activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents.
AID1353599Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Mar-10, Volume: 147Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives.
AID1277591Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in activated caspase-3 level at 200 mg/kg, ip in presence of 25 umol/kg of HO-1 inhibitor ZnPP2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID415440Protection against hydrogen peroxide-induced cell damage in human ECV304 cells treated 30 mins before hydrogen peroxide challenge measured after 6 hrs2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Ligustrazine derivatives. Part 3: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents.
AID1600992Neuroprotective activity in Sprague-Dawley rat model of middle cerebral artery occlusion-induced ischemia-reperfusion injury assessed as decrease in infarct area at 0.7 mmol/kg, ig for 7 days by TTC staining based assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Hybrid molecules of scutellarein and tertramethylpyrazine's active metabolites for ischemic stroke.
AID1277570Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in Evans blue leakage in spinal cord tissue at 200 mg/kg, ip after 24 hrs in presence of 25 umol/kg of HO-1 inhibitor ZnPP2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277610Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as increase in Akt phosphorylation at 200 mg/kg, ip by western blot analysis in presence of Akt inhibitor LY2940022016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1455329Antiproliferative activity against human U87MG cells after 72 hrs in presence of piperlongumine by MTT assay2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Novel Ligustrazine-Based Analogs of Piperlongumine Potently Suppress Proliferation and Metastasis of Colorectal Cancer Cells in Vitro and in Vivo.
AID1277580Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in IL1-beta levels in spinal cord tissue at 200 mg/kg, ip by ELISA in presence of Akt inhibitor LY2940022016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID626517Protection against H2O2-induced toxicity in human ECV304 cells assessed as proliferation rate at 12.5 uM pretreated for 24 hrs before H2O2 challenge measured after 12 hrs by MTT assay2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents.
AID349360Antioxidant activity assessed as inhibition of ROS-induced linoleic acid peroxidation at 2 mM after 15 mins at 100 degC by modified TBARS assay relative to control2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke.
AID1455330Antiproliferative activity against human HCT116 cells after 72 hrs in presence of piperlongumine by MTT assay2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Novel Ligustrazine-Based Analogs of Piperlongumine Potently Suppress Proliferation and Metastasis of Colorectal Cancer Cells in Vitro and in Vivo.
AID1764213Antiproliferation activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents.
AID1277575Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in Evans blue leakage in spinal cord tissue at 200 mg/kg, ip after 48 hrs2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277616Induction of Nrf2 binding to HO-1 promoter in Sprague-Dawley rat model of spinal cord injury at 200 mg/kg, ip by chromatin immunoprecipitation assay in presence of Akt inhibitor LY2940022016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277607Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as increase in HO-1 mRNA expression at 200 mg/kg, ip by real time PCR method in presence of Akt inhibitor LY2940022016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID665461Antioxidant activity assessed as superoxide anion-scavenging activity at 125 to 1000 uM by spectrophotometry2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Novel multi-functional nitrones for treatment of ischemic stroke.
AID1277574Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in Evans blue leakage in spinal cord tissue at 200 mg/kg, ip after 24 hrs in presence of Akt inhibitor LY2940022016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277613Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as increase in Nrf2 mRNA expression at 200 mg/kg, ip by real time PCR method in presence of Akt inhibitor LY2940022016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277569Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as locomotor function recovery at 200 mg/kg, ip measured during 3 to 28 days2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1600982Antioxidant activity against H2O2-induced oxidative stress in rat PC12 cells assessed as cell viability preincubated for 24 hrs followed by H2O2 stimulation further incubated for 5 hrs by MTS assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Hybrid molecules of scutellarein and tertramethylpyrazine's active metabolites for ischemic stroke.
AID1277592Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in activated caspase-3 level at 200 mg/kg, ip in presence of Akt inhibitor LY2940022016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID415442Half life in human2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Ligustrazine derivatives. Part 3: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents.
AID665459Inhibition of platelet aggregation in New Zealand rabbit platelet rich plasma assessed as maximum platelet aggregation at 2 mM after 8 mins by platelet aggregometry (Rvb = 57.3 +/- 8.3%)2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Novel multi-functional nitrones for treatment of ischemic stroke.
AID1628177Induction of apoptosis in human A549/CDDP cells at 0.6 to 1.2 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of New Monocarbonyl Ligustrazine-Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer.
AID626516Protection against H2O2-induced toxicity in human ECV304 cells assessed as proliferation rate at 25 uM pretreated for 24 hrs before H2O2 challenge measured after 12 hrs by MTT assay2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents.
AID415441Antiplatelet activity in rabbit platelets assessed as inhibition of ADP-induced platelet aggregation at 200 uM by aggregometer2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Ligustrazine derivatives. Part 3: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents.
AID1628176Induction of apoptosis in human A549 cells at 2.1 to 4.2 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of New Monocarbonyl Ligustrazine-Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer.
AID1277572Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as locomotor function recovery at 200 mg/kg, ip measured during 3 to 28 days in presence of Akt inhibitor LY2940022016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1455331Antiproliferative activity against human A549 cells after 72 hrs in presence of piperlongumine by MTT assay2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Novel Ligustrazine-Based Analogs of Piperlongumine Potently Suppress Proliferation and Metastasis of Colorectal Cancer Cells in Vitro and in Vivo.
AID1277605Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as increase in HO-1 mRNA expression at 200 mg/kg, ip by real time PCR method2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277609Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as increase in Akt phosphorylation at 200 mg/kg, ip by western blot analysis in presence of 25 umol/kg of HO-1 inhibitor ZnPP2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID295432Protection of hydrogen peroxide-induced damage in ECV304 cells2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Design, synthesis, and biological activities of novel Ligustrazine derivatives.
AID1277588Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as accumulation at G0/G1 phase at 200 mg/kg, ip by TUNEL staining-based flow cytometric analysis in presence of 25 umol/kg of HO-1 inhibitor ZnPP (Rvb = 34.1 %)2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277611Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as increase in Nrf2 mRNA expression at 200 mg/kg, ip by real time PCR method2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277576Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in Evans blue leakage in spinal cord tissue at 200 mg/kg, ip after 48 hrs in presence of 25 umol/kg of HO-1 inhibitor ZnPP2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID1277614Induction of Nrf2 binding to HO-1 promoter in Sprague-Dawley rat model of spinal cord injury at 200 mg/kg, ip by chromatin immunoprecipitation assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID92416Maximum stimulation of proliferation rate of human umbilical vascular endothelial cells (HUVECs) by the compound at a concentration of 0.6 mM2003Bioorganic & medicinal chemistry letters, Jul-07, Volume: 13, Issue:13
Synthesis of the novel liqustrazine derivatives and Their protective effect on injured vascular endothelial cell damaged by hydrogen peroxide.
AID1600981Lipophilicity, logP of compound2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Hybrid molecules of scutellarein and tertramethylpyrazine's active metabolites for ischemic stroke.
AID1628167Inhibition of thioredoxin reductase in human A549 cells by DTNB dye based microplate spectrophotometry2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of New Monocarbonyl Ligustrazine-Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer.
AID1277586Neuroprotective activity in Sprague-Dawley rat model of spinal cord injury assessed as decrease in IL-18 levels in spinal cord tissue at 200 mg/kg, ip by ELISA in presence of Akt inhibitor LY2940022016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,039)

TimeframeStudies, This Drug (%)All Drugs %
pre-199051 (4.91)18.7374
1990's143 (13.76)18.2507
2000's261 (25.12)29.6817
2010's443 (42.64)24.3611
2020's141 (13.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.94 (24.57)
Research Supply Index7.00 (2.92)
Research Growth Index5.05 (4.65)
Search Engine Demand Index52.19 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials41 (3.89%)5.53%
Reviews35 (3.32%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other979 (92.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Bridged Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of TBN in Healthy Subjects [NCT04667013]Phase 116 participants (Anticipated)Interventional2023-12-15Not yet recruiting
Clinical Study of Ligustrazine in Treating Alcohol Addiction [NCT05942352]Phase 4400 participants (Anticipated)Interventional2023-07-28Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]